Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 | P11926 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | BLM | P54132 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180301 | 1.00 | ODC1 (0.42) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL27989280 | 0.94 | ODC1 (0.37) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL157457 | 0.94 | ODC1 (0.37) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL181191 | 0.94 | ODC1 (0.37) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL30156940 | 0.94 | ODC1 (0.37) | ODC1LMNABLMKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL21225312 | 0.92 | BLM (0.39) | ODC1LMNABLMKDM4EMAPT | |
| Water SCHEMBL21225404 | 0.92 | ODC1 (0.36) | ODC1LMNABLMKDM4EMAPT | |
| Tetradecane SCHEMBL27774110 | 0.91 | DNM1 (0.40) | ODC1KMT2ATSHRFDPSMEN1 | |
| SCHEMBL27466000 | 0.87 | GGT1 (0.33) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL9595205 | 0.86 | ODC1 (0.41) | ODC1LMNABLMKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230139922-A1 | BACITRACIN-ALGINATE OLIGOMER CONJUGATES | ALGIPHARMA AS (NO) | 2023-05-04 | — | — | US | claimed |
| EP-3528830-B1 | POLYMYXIN-ALGINATE OLIGOMER CONJUGATES | ALGIPHARMA AS (NO) | 2022-10-05 | — | — | EP | claimed |
| US-20200138728-A1 | CATIONIC MATERIALS AND FORMULATIONS FOR DRUG DELIVERY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2020-05-07 | — | — | US | claimed |
| US-20190328833-A1 | POLYMYXIN-ALGINATE OLIGOMER CONJUGATES | ALGIPHARMA AS (NO) | 2019-10-31 | — | — | US | claimed |
| EP-3528829-A1 | BACITRACIN-ALGINATE OLIGOMER CONJUGATES | Algipharma AS (NO) | 2019-08-28 | — | — | EP | claimed |
| EP-3528830-A1 | POLYMYXIN-ALGINATE OLIGOMER CONJUGATES | Algipharma AS (NO) | 2019-08-28 | — | — | EP | claimed |
| US-20180318231-A1 | CATIONIC MATERIALS AND FORMULATIONS FOR DRUG DELIVERY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2018-11-08 | — | — | US | claimed |
| US-10022334-B2 | Cationic materials and formulations for drug delivery | The Brigham and Women's Hostpital, Inc. (US) | 2018-07-17 | — | — | US | claimed |
| WO-2018073448-A1 | BACITRACIN-ALGINATE OLIGOMER CONJUGATES | ALGIPHARMA AS (NO) | 2018-04-26 | — | — | WO | claimed |
| WO-2018073449-A1 | POLYMYXIN-ALGINATE OLIGOMER CONJUGATES | ALGIPHARMA AS (NO) | 2018-04-26 | — | — | WO | claimed |
| US-20160338970-A1 | CATIONIC MATERIALS AND FORMULATIONS FOR DRUG DELIVERY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-24 | — | — | US | claimed |
| WO-2015099985-A2 | CATIONIC MATERIALS AND FORMULATIONS FOR DRUG DELIVERY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-07-02 | — | — | WO | claimed |
| US-8048852-B2 | Antimicrobial compounds and formulations | LYTIX BIOPHARMA AS (NO) | 2011-11-01 | — | — | US | claimed |
| US-20100267621-A1 | Antimicrobial Compounds and Formulations | LYTIX BIOPHARMA AS (NO) | 2010-10-21 | — | — | US | claimed |
| EP-4742904-A1 | CONJUGATES OF ANTIMICROBIAL AGENT AND A LINKER MOIETY SUITABLE FOR COVALENT ATTACHMENT TO MATERIALS AND SUBSTRATES | Amicoat AS (NO) | 2026-05-20 | — | — | EP | disclosed |
| EP-4646423-A1 | PEPTIDE SYNTHESIS METHOD INVOLVING STERICALLY HINDERED TRI-TERT-BUTYL-TRYPTOPHAN (TBT) RESIDUE | Amicoat AS (NO) | 2025-11-12 | — | — | EP | disclosed |
| US-20250332217-A1 | IMMUNE CHECKPOINT INHIBITOR COMBINATIONS | LYTIX BIOPHARMA AS (NO) | 2025-10-30 | — | — | US | disclosed |
| US-20030195144-A1 | Antimicrobial compounds and formulations | LYTIX BIOPHARMA AS (NO) | 2003-10-16 | — | — | US | disclosed |
| EP-1263471-A2 | ANTIMICROBIAL COMPOUNDS AND FORMULATIONS | ALPHARMA AS (NO) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001066147-A2 | ANTIMICROBIAL COMPOUNDS AND FORMULATIONS | ALPHARMA AS (NO) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200138728-A1 | CATIONIC MATERIALS AND FORMULATIONS FOR DRUG DELIVERY | SLC7A1, SLC43A1, AADAT | ODC1 1977/4885LMNA 224/4885BLM 3268/4885 |
| US-20180318231-A1 | CATIONIC MATERIALS AND FORMULATIONS FOR DRUG DELIVERY | SLC7A1, SLC43A1, AADAT | ODC1 1977/4885LMNA 224/4885BLM 3268/4885 |
| US-20100267621-A1 | Antimicrobial Compounds and Formulations | VIP, NONO, CLPTM1 | ODC1 2309/4885LMNA 2797/4885BLM 2884/4885 |
| US-20230139922-A1 | BACITRACIN-ALGINATE OLIGOMER CONJUGATES | HDAC6, GNE, TBCA | ODC1 1596/4885LMNA 2132/4885BLM 625/4885 |
| US-20160338970-A1 | CATIONIC MATERIALS AND FORMULATIONS FOR DRUG DELIVERY | SLC7A1, SLC43A1, AADAT | ODC1 2146/4885LMNA 200/4885BLM 3298/4885 |
| US-10022334-B2 | Cationic materials and formulations for drug delivery | SLC7A1, SLC43A1, AADAT | ODC1 2146/4885LMNA 200/4885BLM 3298/4885 |
| US-20030195144-A1 | Antimicrobial compounds and formulations | LPO, CLPTM1, VIP | ODC1 2699/4885LMNA 2006/4885BLM 2761/4885 |
| US-20190328833-A1 | POLYMYXIN-ALGINATE OLIGOMER CONJUGATES | GNE, ALG1, ALG8 | ODC1 3016/4885LMNA 2125/4885BLM 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.